Multiply Labs
Multiply Labs builds physical AI robotic systems that automate pharmaceutical biomanufacturing for cell therapies, gene therapies, and biologics. It sells modular Robotic Cluster systems, software, and consumables to large pharma and biotech companies.
- Company typePrivate
- Founded2016
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Multiply Labs does
Multiply Labs, Inc. is a San Francisco-based robotics company founded in 2016 that builds physical AI systems for automated biomanufacturing of personalized pharmaceutical capsules, cell therapies, gene therapies, and biologics. Its core product, the Robotic Cluster, integrates four Universal Robots cobots with up to 24 instrument modules in under 600 square feet, automating 50+ discrete unit operations inside a closed, GMP-compliant environment. The platform's software stack includes the no-code Process Creator App, a 21 CFR Part 11 compliant manufacturing execution system, and the Resonance imitation-learning pipeline that captures process knowledge from expert video demonstrations. The company has established a broad instrument-partner ecosystem (Thermo Fisher, Cytiva, Charles River, GenScript, Wilson Wolf, Fedegari, Akron Bio, ChemoMetec, CPC Biotech) and technology partnerships with NVIDIA (Isaac, GR00T) and Universal Robots. The firm is venture-backed with approximately $41.3M raised over seven rounds, has ~52 employees, and is led by co-founders Fred Parietti (CEO) and Alice Melocchi (CSO).
The company sells its robotic cluster systems, consumables, and software via direct enterprise field sales to large pharmaceutical and biotech companies. Pricing is quote-based and structured as multi-year contracts, with deployments supported through on-site facility visits. Named enterprise customers include AstraZeneca, Legend Biotech, Kyverna Therapeutics, WuXi STA, and Stanford GMP Facility. The Italian manufacturing subsidiary (Multiply Labs Italia) was established in May 2026 in Turin to scale cluster production. Quantified performance claims include a 74% reduction in cost per dose (from $100,000 to $25,000-$35,000) and up to 100x throughput per square foot of cleanroom space relative to manual processes, with 90% of cleanroom steps automated. Revenue is not publicly disclosed, and the company is in an early-commercial phase transitioning from pilot deployments to scaled manufacturing.
Multiply Labs firmographics
Firmographics- Name
- Multiply Labs
- Legal name
- Multiply Labs, Inc.
- Website
- https://multiplylabs.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Multiply Labs builds physical AI robotic systems that automate pharmaceutical biomanufacturing for cell therapies, gene therapies, and biologics. It sells modular Robotic Cluster systems, software, and consumables to large pharma and biotech companies.
- Ownership category
- akta.pro rank
Multiply Labs industry classification
Industry- Product category
- Robotic Biomanufacturing Systems
- NAICS
- Other General Purpose Machinery Manufacturing (3339), Commercial and Service Industry Machinery Manufacturing (3333)
- SIC
- Special Industry Machinery, Nec (3559), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
- akta.pro secondary industries
- Lab Automation, Instrument Control & Workflow Orchestration Software (HLAGAJAG), Collaborative Robots (Cobots) (IMAHAHAB), Robotic Process Automation (RPA) & Hyperautomation Platforms (HDAEAKAF), Robotic Process Automation (RPA) & Digital Robotics (HDAAAIAI)
Keywords
Where Multiply Labs is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Multiply Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Robotic Cluster Systems: Sale of robotic cluster systems to pharmaceutical companies for cell therapy and biologics manufacturing. The clusters are modular systems that can be configured per customer process and therapy type, with pricing likely based on configuration and throughput requirements.
- Software and Process Control: Software licensing for process automation, real-time monitoring, and quality system integration. The Process Creator App and 21 CFR Part 11 compliant electronic records system likely generate ongoing software licensing revenue.
- Consumables: Purpose-engineered consumables for robotic handling including G-Rex Cartridges, Cell Culture Bag Cartridges, NC-Cassette Cartridges, Syringe Cartridges, Vial Cartridges, DFP Cartridges, and Waste Bin Cartridges.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise pricing based on cluster configuration and throughput requirements |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Multiply Labs product offering
Product offeringCore offering
Multiply Labs builds a modular robotic biomanufacturing platform — the Robotic Cluster — that connects existing GMP instruments inside a closed, automated environment using four Universal Robots cobots operating in parallel with proprietary orchestration software. The system automates 50+ unit operations for cell therapy, gene therapy, antibody, recombinant protein, vaccine, and RNA therapy manufacturing, paired with a 21 CFR Part 11 compliant software control platform and a no-code Process Creator App. Purpose-engineered consumable cartridges support robotic handling, while the Resonance auto-training pipeline enables imitation learning from video demonstrations.
Product overview
Multiply Labs offers a modular biomanufacturing platform centered on the Robotic Cluster—a system that integrates four Universal Robots cobots operating in parallel with up to 24 instrument modules in under 600 square feet. The platform is designed to automate existing GMP instruments without process transfer or lock-in. Key components include the Process Creator App (drag-and-drop no-code process builder), Software Control Platform (21 CFR Part 11 compliant execution and monitoring), and Unit Operations Automation covering 50+ operations. Purpose-engineered Consumables support robotic handling. Advanced capabilities include NVIDIA-powered Physical AI integration (digital twins, Isaac, GR00T), Resonance auto-training pipeline for imitation learning, and real-time anomaly detection. The platform targets cell therapy, gene therapy, antibodies, recombinant proteins, vaccines, and RNA therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- Robotic Cluster Modular robotic manufacturing system packing four Universal Robots cobots and up to 24 instrument modules into under 600 square feet, connecting existing GMP instruments inside a closed, automated environment. Targets up to 100x throughput increase and 74% cost reduction per dose for cell therapy, gene therapy, and biologics manufacturing.
- Software Control Platform Manufacturing execution software that translates manufacturing protocols into robotic execution, collects every sensor reading and interaction in real time, and delivers complete 21 CFR Part 11 compliant electronic records directly to customer quality systems.
- Process Creator App (PCA) No-code, drag-and-drop interface that enables scientists to build, modify, and own their manufacturing process by visually sequencing unit operations without programming expertise.
- Consumables Portfolio Portfolio of purpose-engineered consumable cartridges designed for robotic handling, including G-Rex Cartridge, Cell Culture Bag Cartridge, NC-Cassette Cartridge, Syringe Cartridge, Vial Cartridge, DFP Cartridge, and Waste Bin Cartridge.
Quantifiable outcome
- 74% reduction in manufacturing costs per dose, from $100,000 to $25,000-$35,000
- +4 more outcomes
Companies that use Multiply Labs
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles3 records
Multiply Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration11 records
AI capability7 records
Feature6 records
Multiply Labs partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship, core and minor.
- AstraZenecaflagshipMultiply Labs announced an agreement with AstraZeneca to evaluate GMP-ready robotic systems for commercial-scale cell therapy manufacturing. The collaboration focuses on end-to-end robotic automation of industry-standard instruments to enable scalable, high-throughput manufacturing while meeting clinical and commercial quality standards.
- NVIDIAcoreMultiply Labs partnered with NVIDIA to deploy physical AI robotics and simulation technologies including Isaac and GR00T into robotic biomanufacturing systems for cell and gene therapies. The collaboration uses digital twins, foundation models, and perception pipelines to increase consistency and efficiency in advanced therapy manufacturing.
- Thermo Fisher ScientificcoreMultiply Labs expanded collaboration with Thermo Fisher Scientific to integrate robotic automation with the Gibco CTS DynaCellect Magnetic Separation System. The partnership enables customers to achieve end-to-end automation in cell therapy manufacturing processes.
- Kyverna TherapeuticscoreMultiply Labs partnered with Kyverna Therapeutics to pilot robotic automation for cell therapy manufacturing. The partnership evaluates automation of Kyverna's KYV-102 CAR-T candidate manufacturing using Multiply Labs' robotic systems, aiming to reduce labor costs and increase manufacturing efficiency.
- Legend BiotechcoreMultiply Labs and Legend Biotech announced a collaboration to automate cell therapy production through robotics. Legend Biotech receives priority access to Multiply Labs' automated systems for manufacturing their CAR-T therapies including Carvykti.
- WuXi STAcoreWuXi STA and Multiply Labs partnered to deploy robotic manufacturing technology for personalized medications. The robotic system enables manufacturing of advanced solid oral dosage forms including personalized capsules with various formulation types for clinical and commercial production.
- Universal RobotscoreUniversal Robots provides the cobots (robotic arms) that power Multiply Labs' robotic clusters, running proprietary orchestration code for parallel operation.
- Retro BiosciencesminorRetro Biosciences partnered with Multiply Labs for cell therapy manufacturing automation as part of their $85 million partnership for longevity research.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Multiply Labs competitors and assessment
Company assessmentOthers
- Universal Robots: Universal Robots is the cobot supplier whose arms power Multiply Labs' robotic cluster. It is a critical technology partner and enabling infrastructure provider rather than a direct competitor, though it could potentially expand into end-to-end biomanufacturing automation offerings.
Broad incumbents
- Lonza: Lonza is a leading CDMO with major cell and gene therapy manufacturing capacity. Lonza competes with Multiply Labs' customers in the contract manufacturing space and is also investing in automation of its own facilities, making it both a potential competitor and a potential customer.
- Cytiva: Cytiva (a Danaher company) is a major bioprocessing equipment and consumables provider that supplies instruments (Xuri bioreactor, cell processing tools) integrated with Multiply Labs' clusters. Cytiva could expand into more fully integrated automation, competing with Multiply Labs while also serving as a partner ecosystem.
- ABB: ABB is a major industrial automation and robotics company (including via its ASTI Mobile Robotics and collaborative robot offerings). ABB is a broad incumbent that could compete with Multiply Labs in pharmaceutical manufacturing automation, though its current focus is broader industrial applications.
- Thermo Fisher Scientific: Thermo Fisher Scientific provides Gibco CTS cell therapy instruments (DynaCellect, Rotea) that Multiply Labs integrates. As a dominant life sciences tools company, Thermo Fisher could develop competing end-to-end automation solutions while remaining a key instrument partner to Multiply Labs.
Direct peers
- Ori Biotech: Ori Biotech provides a fully automated cell and gene therapy manufacturing platform (Ori Cell Processing System) targeting developers of advanced therapies. Both companies are direct competitors in automating closed-system, scalable cell therapy production for clinical and commercial use.
- Cellares: Cellares is a direct competitor developing automated, closed-system cell therapy manufacturing platforms (Cell Shuttle). Both companies target cell and gene therapy manufacturers with integrated robotic bioprocessing solutions that promise higher throughput and lower cost per dose than manual methods.
- Miltenyi Biotec: Miltenyi Biotec offers the Prodigy and MACS platforms for automated cell processing and manufacturing. Both companies target cell therapy developers with integrated instrument-plus-software solutions, and Miltenyi is a competitor in the cell therapy automation niche.
Emerging players
- Cellular Origins: Cellular Origins is an early-stage UK company developing robotic, configurable cell therapy manufacturing platforms. Both companies use modular robotic systems to automate cell therapy production, with Cellular Origins focused initially on autologous cell therapy workflows.
- ScaleReady: ScaleReady offers the G-Rex-based cell therapy manufacturing platform and process development services. Both companies focus on automating and scaling cell therapy production, with ScaleReady's G-Rex cartridges integrated into Multiply Labs' consumables portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Multiply Labs social profiles
Digital presenceMultiply Labs compliance and trust
Trust signalCompliance1 record
Multiply Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Multiply Labs leadership team
Management profileNumber of profiles
Profiles12 records
Multiply Labs subsidiaries and ownership
Company hierarchySubsidiaries1 record
Multiply Labs funding detail
Funding detailFunding overview
Funding rounds5 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Multiply Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Multiply Labs
What does Multiply Labs do?
Multiply Labs builds a modular robotic biomanufacturing platform — the Robotic Cluster — that connects existing GMP instruments inside a closed, automated environment using four Universal Robots cobots operating in parallel with proprietary orchestration software. The system automates 50+ unit operations for cell therapy, gene therapy, antibody, recombinant protein, vaccine, and RNA therapy manufacturing, paired with a 21 CFR Part 11 compliant software control platform and a no-code Process Creator App. Purpose-engineered consumable cartridges support robotic handling, while the Resonance auto-training pipeline enables imitation learning from video demonstrations.
Is Multiply Labs a public or private company?
Multiply Labs is a private company. It is classified as venture growth investor backed and is currently operating.
When was Multiply Labs founded?
Multiply Labs was founded in 2016. It employs 11 to 50 people.
Where is Multiply Labs based?
Multiply Labs is headquartered in San Francisco, United States, in the North America region.
How does Multiply Labs make money?
Three revenue lines are on record. Robotic Cluster Systems are the primary driver. The others are software and Process Control and consumables.
Who are Multiply Labs's main competitors?
Universal Robots is listed as an others. Broad incumbents are Lonza, Cytiva, ABB and Thermo Fisher Scientific. Direct peers are Ori Biotech, Cellares and Miltenyi Biotec. Emerging players are Cellular Origins and ScaleReady.
Does Multiply Labs have an API?
No public API is recorded for Multiply Labs.
What industry is Multiply Labs in?
Multiply Labs's product category is Robotic Biomanufacturing Systems. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAGAJAG, Lab Automation, Instrument Control & Workflow Orchestration Software. Its NAICS code is 3339 and its SIC code is 3559.